Technology Insight: pharmacoproteomics for cancer—promises of patient-tailored medicine using protein microarrays
Julia D Wulfkuhle*, Kirsten H Edmiston, Lance A Liotta and Emanuel F Petricoin III*
Correspondence *10900 University Blvd, Manassas, VA 20110, USA
Email jwulfkuh@gmu.edu
Email epetrico@gmu.edu
Proteomics can help to define and identify patients that will most benefit from the increasing number of molecular-targeted agents. In particular, reverse phase protein microarray provides detailed information about the state of the cellular 'circuitry' from small samples such as patient biopsy specimens. This review discusses the clinical applications of this emerging technology and how it could be used to help guide individualized treatment approaches.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Protein biomarker discovery and validation: the long and uncertain path to clinical utilityNature Biotechnology Research (01 Aug 2006)